

## Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
<b>Name</b>	<b>Name</b>
<b>ID Number</b>	<b>Specialty</b>
<b>D.O.B.</b> ____/____/____ MM/DD/YYYY <input type="checkbox"/> Male <input type="checkbox"/> Female	<b>Address</b>
<b>Diagnosis</b>	<b>City /State/Zip</b>
<b>Drug Name</b> <b>Stelara IV</b>	<b>Phone:</b>
<b>Dose and Quantity</b>	<b>Fax:</b>
<b>Directions</b>	<b>NPI</b>
<b>Date of Service(s)</b>	<b>Contact Person</b>
	<b>Contact Person Phone / Ext.</b>

**STEP 1: DISEASE STATE INFORMATION**

**Required Demographic Information:**

*Patient Weight:* \_\_\_\_\_ *kg*  
*Patient Height:* \_\_\_\_\_ *ft*    \_\_\_\_\_ *inches*

Will the provider be administering the medication to the FEP member within the health plan’s geographic service area?  
 Yes    No   *If No, a prior authorization is not required through this process.*

**Prior authorizations are required for FEP members that will be serviced by a provider within the health plan’s geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member’s benefit requirements.**

Is this member’s FEP coverage primary or secondary coverage?  
 If primary, continue with question set.  
 If secondary, **an authorization is not needed through this process. Please contact the member’s primary coverage for determination of benefit and additional information.**

**Site of Care:**

- A. At what location will the member be receiving the requested medication?
- Physician’s office, home infusion, non-hospital affiliated ambulatory infusion center.
  - Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting. \_\_\_\_\_
  - Other. Please specify. \_\_\_\_\_

**Criteria Questions:**

1. Is this a request for initiation of therapy with Stelara? Yes No
2. What is the patient's diagnosis?
  - Crohn's Disease (CD)
    - a. Does the patient have a diagnosis of moderate to severely active Crohn's Disease? Yes No
  - Ulcerative Colitis (UC)
    - a. Does the patient have a diagnosis of moderate to severely active Ulcerative Colitis? Yes No
  - Other diagnosis (*please specify*): \_\_\_\_\_
3. Does the patient have a contraindication to or have they had either an inadequate response or intolerance to at least one conventional therapy option? Yes No
4. Will the patient's initial dosing be one IV infusion? Yes No
5. What is the patient's weight in either pounds (lbs) or kilograms (kg)? *Please select answer below:*
  - Less than 55kg (121lbs):** Does the prescriber agree to administer 260mg for the initial IV infusion? Yes No
  - 55kg (121lbs) to 85kg (187lbs):** Does the prescriber agree to administer 390mg for the initial IV infusion? Yes No
  - Greater than 85kg (187lbs):** Does the prescriber agree to administer 520mg for the initial infusion? Yes No
6. Has the patient been tested for latent tuberculosis (TB)? Yes\* No
  - \*If YES,* what was the result of the TB test? Negative Positive\*
  - \*If POSITIVE,* is the patient currently receiving treatment or has the patient already completed treatment for TB? Yes No
7. Does the patient have any active infections including tuberculosis (TB) and Hepatitis B Virus (HBV) infection? Yes No
8. Will the patient be given live vaccines while on Stelara therapy? Yes No
9. Will Stelara be used in combination with another biologic disease-modifying antirheumatic drug (DMARD)\* or targeted synthetic DMARD? Yes No
  - \*DMARD includes: Actemra, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Inflectra, Kevzara, Kineret, Orencia, Otezla, Remicade, Renflexis, Rituxan, Siliq, Simponi, Taltz, Tremfya, and Xeljanz*

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required)

**Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.**

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
<b>Step 2:</b> Checklist	<input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Provide chart notes	<input type="checkbox"/> Attach test results
<b>Step 3:</b> Submit	<b>By Fax: BCBSM Specialty Pharmacy Mailbox</b> 1-877-325-5979	<b>By Mail: BCBSM Specialty Pharmacy Program</b> P.O. Box 312320, Detroit, MI 48231-2320

**Confidentiality notice:** This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.